Manufacturers have depended on service providers to manage their copay and voucher systems for a long time, and for good reason. Companies like TrialCard, ConnectivRx, OptimizeRx or McKesson Life Sciences (which contains the old McKesson Patient Relationship Solutions business) manage […]
Read More
Jim Greenwood, a former Congressman who has led the Biotechnology Innovation Organization since 2005, is stepping down, to be replaced on June 1 by McMurry-Heath, MD, PhD as president and CEO. She will be only the third head of the […]
Read MoreThe Milken Institute, through its FasterCures effort, had set up a Covid-19 tracking system in late March to collect data on vaccines and therapies for the disease (and now there are multiple other efforts, including one from IQVIA). At that […]
Read MoreIn the past two years, four new cell and gene therapies have entered the US market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million per treatment. Payers are concerned about the high cost, especially since […]
Read More
For over a decade, the IT developer Model N has been promoting the concept of revenue management (RM) to organize the disparate commercial functions (sales, marketing, trade relations, government pricing, etc.) of life sciences firms to minimize revenue losses from […]
Read MoreNow calling itself “the industry’s most comprehensive and scalable data and business-process platform for commercialization and market access of cell and gene therapy, specialty, and retail pharmaceuticals” (whew!), Integrichain is acquiring the Life Sciences Division of Cumberland. Both companies are […]
Read MoreOn April 1, having passed through governmental regulatory reviews, the acquisition of assets of GE Healthcare Life Sciences by Danaher Corp was formally completed. The new entity, part of Danaher’s “Life Sciences Platform” (which includes other brands like Beckman Coulter, […]
Read MoreThe man-in-the-street view of the controversy around chloroquine and its alternative form, hydroxychloroquine, goes something like this: tests performed somewhere (France and China?) indicated its efficacy, but a slow-to-act FDA hasn’t authorized its use even when it could save thousands […]
Read More
The IQVIA Institute of Human Data Science’s annual study, Global Medicine Spending and Usage Trends, is out and while its data are a reliable measure of past years, and a well-grounded forecast of the next five years, the study does […]
Read MoreThe Boyd Co., a boutique firm that specializes in site selection analysis, has completed a study of global construction/operations costs for life sciences facilities. The “loser” (highest total annual operating costs): Copenhagen, Denmark; the “winner” was Bangalore, India (while Japan, […]
Read More
